Welcome to our dedicated page for Ovid Therapeutics news (Ticker: OVID), a resource for investors and traders seeking the latest updates and insights on Ovid Therapeutics stock.
Ovid Therapeutics Inc. (Nasdaq: OVID) is a New York‑based biopharmaceutical company developing small molecule medicines for brain conditions driven by excess neural excitability. The OVID news feed on Stock Titan aggregates company‑issued press releases and other coverage that detail its clinical progress, financing activities and corporate developments.
News about Ovid frequently highlights updates on its lead programs. These include OV329, a next‑generation GABA‑aminotransferase (GABA‑AT) inhibitor being developed as a potential therapy for treatment‑resistant seizures, and a portfolio of potassium‑chloride cotransporter 2 (KCC2) direct activators, such as OV350 and OV4071, for multiple central nervous system disorders. Company announcements describe Phase 1 results, biomarker data, safety and tolerability findings, and plans for subsequent clinical studies in drug‑resistant epilepsies and neuropsychiatric indications.
Investors following OVID news will also see disclosures on capital formation and strategic transactions, such as private placement financings involving Series B convertible preferred stock and warrants, and the sale of future ganaxolone royalty rights to Immedica Pharma AB. Regulatory and listing‑related updates, including interactions with The Nasdaq Stock Market regarding bid price compliance and share authorization, are reported through SEC‑related press releases and proxy materials.
Corporate governance items, such as leadership succession plans, executive appointments and special or annual meeting outcomes, appear regularly in Ovid’s news flow. These updates provide context on how the company is organizing its management and board to support its CNS‑focused pipeline.
By reviewing the OVID news page, readers can track how Ovid Therapeutics communicates progress on OV329, its KCC2 direct activator franchise, financing events and key regulatory or governance milestones over time.
Ovid Therapeutics announced advancements in its business development program, aiming to enhance its pipeline of CNS medicines. The company is currently enrolling patients in two pivotal Phase 3 trials for soticlestat targeting Lennox-Gastaut and Dravet syndromes. As of Q3 2021, Ovid reported $201.8 million in cash and equivalents, with zero revenue compared to $6.9 million in Q3 2020. The company’s net loss narrowed to $11.4 million, improving from $16.4 million year-over-year. Ovid plans to submit three INDs in three years, with OV329 targeted for 2022.
Ovid Therapeutics Inc. (NASDAQ: OVID) has appointed Dr. Kevin Fitzgerald to its Board of Directors. Dr. Fitzgerald brings over 20 years of experience in drug discovery, currently serving as Chief Scientific Officer at Alnylam Pharmaceuticals. His expertise in transforming scientific innovations into commercial medicines is expected to enhance Ovid's neuroscience development programs. Ovid focuses on developing therapies for rare neurological diseases, and Fitzgerald's addition is anticipated to strengthen the company's strategic approach in targeting central nervous system disorders.
Ovid Therapeutics (NASDAQ: OVID) announced a virtual presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13, 2021, at 7:00 a.m. EDT. The event will feature on-demand viewing, accessible through the company's website. Ovid is focused on developing treatments for neurological diseases, with a pipeline that includes OV329 for seizures related to Tuberous Sclerosis Complex, OV882 for Angelman syndrome, and OV815 for KIF1A associated neurological disorders. The company also has significant interests in soticlestat, currently under development for Dravet syndrome and Lennox-Gastaut syndrome.
Ovid Therapeutics reported zero revenue for Q2 2021 and a net loss of $15.8 million, improving from a $22.6 million loss in Q2 2020. The company ended the quarter with $212.2 million in cash. Operating expenses were $14.3 million, with adjusted operating expenses of $10.0 million, aligning with guidance. Leadership appointments aim to enhance its neuroscience focus, including Dr. Michael Poole to the board. Ovid terminated a previous agreement with Takeda for soticlestat, transferring R&D responsibilities while retaining milestone and royalty rights.
Ovid Therapeutics (NASDAQ: OVID) announced significant leadership changes aimed at advancing its neuroscience initiatives. Dr. Michael Poole joins the Board, bringing over 30 years of expertise. Dr. Claude Nicaise has been appointed Head of R&D, while Jason Tardio becomes Chief Operating Officer. The company is focusing on early-stage development and has reduced its workforce by 25% to streamline operations. Dr. Amit Rakhit transitions to the Scientific and Clinical Advisory Board after contributing significantly to Ovid's management team.
Ovid Therapeutics announced its participation in the Ladenburg Thalmann 2021 Healthcare Conference on July 14, 2021, at 9:30 a.m. ET. The presentation will be conducted virtually, and interested individuals can access a live webcast on the Company's website. An archived replay will be available afterward. Ovid is focused on developing treatments for rare neurological diseases, featuring a pipeline that includes therapies for Tuberous Sclerosis Complex, Angelman syndrome, and other conditions.
Ovid Therapeutics Inc. (NASDAQ: OVID) announces that Chief Business Officer Jeffrey Rona has expanded his role to include Chief Financial Officer responsibilities, streamlining its corporate strategy. CEO Jeremy Levin highlighted this move as essential for enhancing operational efficiency. Rona, with over 25 years of experience in life sciences, expressed enthusiasm for leading the company's growth strategies. Ovid continues to focus on developing therapies for rare neurological disorders, with pipeline programs including OV329, OV882, and OV815.
Ovid Therapeutics Inc. (NASDAQ: OVID) recently announced the appointment of Joy A. Cavagnaro, Ph.D., and Bruce A. Sullenger, Ph.D., to its Scientific Advisory Board. These appointments aim to enhance Ovid's neuroscience expertise and drive development in rare neurological diseases. Dr. Cavagnaro brings over 30 years of experience in biotechnology and preclinical development, while Dr. Sullenger is a pioneer in translational research and RNA technology. Both are expected to significantly contribute to Ovid's mission of developing innovative treatments.
Ovid Therapeutics has closed a significant royalty, license, and termination agreement with Takeda for the investigational medicine soticlestat, receiving an upfront payment of $196.0 million with potential milestone payments up to $660.0 million and double-digit royalties on future sales. The company reported first-quarter 2021 revenue of $208.4 million, a stark increase from zero in the previous year, with a net income of $176.0 million. However, it terminated its agreement with Angelini Pharma and will discontinue the OV101 program for Angelman syndrome.
Ovid Therapeutics (NASDAQ: OVID) will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 9:10 a.m. ET. Investors can access the live audio webcast on the Company’s website, with an archived replay available afterward. Ovid focuses on developing therapies for rare neurological diseases using its BoldMedicine® approach. Its pipeline includes promising candidates addressing disorders such as Tuberous Sclerosis Complex and Angelman syndrome, with significant collaborations and research underway.